Related Experiment Videos
Current concepts in mild cognitive impairment.
R C Petersen1, R Doody, A Kurz
1Department of Neurology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA. peter8@mayo.edu
Archives of Neurology
|December 26, 2001
Summary
Mild cognitive impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease (AD). Individuals with MCI show accelerated progression to AD, making it a key focus for early therapeutic interventions.
Area of Science:
- Neurology
- Geriatrics
- Neuropsychology
Background:
- Aging and dementia research focuses on early cognitive impairment.
- Mild cognitive impairment (MCI) is a recognized transitional state between normal aging and Alzheimer's disease (AD).
- MCI is characterized by memory loss exceeding age-expected norms, without meeting criteria for probable AD.
Purpose of the Study:
- To summarize the current state of knowledge on MCI.
- To review scientific literature on aging and MCI.
- To provide recommendations on MCI diagnosis, management, and ethics.
Main Methods:
- Convened international experts in neurology, psychiatry, geriatrics, neuropsychology, neuroimaging, neuropathology, clinical trials, and ethics.
- Reviewed global scientific literature on aging and MCI.
- Summarized evidence regarding MCI diagnostic criteria, clinical outcomes, and ethical considerations.
Main Results:
- MCI represents a high-risk condition for developing probable AD.
- Individuals with MCI progress to probable AD at an accelerated rate compared to healthy individuals.
- Heterogeneity in MCI terminology was noted, with suggestions for subclassifications.
Conclusions:
- MCI is a critical area for potential therapeutic intervention, with ongoing international clinical trials.
- No current treatments are recommended for MCI, but research is advancing.
- Recommendations were made regarding ethical issues in MCI diagnosis and management.